Methylphenidate Lp Viatris (Methylphenidate Hydrochloride)

Methylphenidate hydrochloride works by inhibiting the reuptake of dopamine and norepinephrine at neuronal synapses. This increases the levels of these neurotransmitters in the brain, enhancing signaling pathways that regulate attention, impulse control, and arousal, which underlies its therapeutic effects in ADHD and narcolepsy.

The appropriate dose of Methylphenidate Lp Viatris is determined individually by a qualified prescriber based on the patient’s age, clinical condition, response to therapy, and any relevant medical factors. Dosage adjustments are made according to therapeutic response and tolerability.

Methylphenidate Lp Viatris is classified as Pregnancy Category C, indicating that risk cannot be ruled out and it should only be used if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so breastfeeding is generally not recommended while taking this medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Methylphenidate Lp Viatris belongs to the methylphenidate class, which differs from amphetamine‑based stimulants in its chemical structure and pharmacokinetic profile. While both classes improve attention and reduce hyperactivity, methylphenidate generally has a shorter half‑life and may be preferred for patients who respond better to its specific mechanism or who require flexible dosing.

Methylphenidate Lp Viatris should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Methylphenidate Lp Viatris is taken orally, usually with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed, crushed, or broken unless specifically instructed by a healthcare professional.

Serious risks include cardiovascular events such as hypertension, tachycardia, or chest pain; psychiatric effects like new or worsening psychosis, hallucinations, or severe mood changes; and rare but severe allergic reactions. Patients should be monitored closely for these events, especially during treatment initiation or dose changes.

Methylphenidate Lp Viatris is contraindicated in individuals with known hypersensitivity to methylphenidate or any excipients, those taking monoamine oxidase inhibitors (MAOIs) within the past 14 days, and patients with severe anxiety, agitation, glaucoma, or significant cardiovascular disease unless a specialist determines the benefits outweigh the risks.